Polycystic Ovarian Syndrome (PCOS) Biomarker Evaluation Study
ConditionPolycystic Ovarian Syndrome (PCOS)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age15-25
SponsorUniversity Hospital Erlangen
About this trial
The purpose of the study is to validate recently identified biomarkers for the identification of PCOS in adolecent and young adult women.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Female subjects age 15-25 years
Signed written informed consent
Disqualifiers
Less than 1 years from onset of menarche
Use of hormonal contraceptives
Documented ongoing pregnancy
Major ovarian abnormalities, including subject with only one ovary, cysts and solid masses > 2 cm as detected by transvaginal ultrasound
Trial population
Adolescent and young adult women aged between the ages of 15 and 25 with and without PCOS who present at the Women's Clinic of the University Hospital Erlangen.
Trial design
Design model
Case-control
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
380 Participants
are grouped into 2 trial groupsGroup A: Women with PCOS
Group B: Women without PCOS (controls)
Trial outcomes
Primary outcomes
1
The validation of new potential biomarkers for aid in the diagnoisis of PCOS in adolescent and young adult women
Time frame
BaselineSponsors and contacts
Click on the lead sponsor to view all of their trials.
University Hospital Erlangen
Lead sponsor
Roche Diagnostics International AG
Collaborator
Source ClinicalTrials.gov